2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD3

CD3

Cluster of differentiation 3

CD3 (cluster of differentiation 3) is a protein complex and T cell co-receptor that is involved in activating both the cytotoxic T cell (CD8+ naive T cells) and T helper cells (CD4+ naive T cells). It is composed of four distinct chains. In mammals, the complex contains a CD3γ chain, a CD3δ chain, and two CD3ε chains. These chains associate with the T-cell receptor (TCR) and the CD3-zeta (ζ-chain) to generate an activation signal in T lymphocytes. The TCR, CD3-zeta, and the other CD3 molecules together constitute the TCR complex.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99623
    Flotetuzumab
    		98.71%
    Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML).
    Flotetuzumab
  • HY-P990608
    Alpitatug
    		99.13%
    Alpitatug (IMC 3C5) is a CHO-expressed human antibody that targets KLK2/Kallikrein 2. Alpitatug has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.3 kDa. The isotype control for Alpitatug can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Alpitatug
  • HY-P991055
    Forimtamig
    		Inhibitor 99.96%
    Forimtamig (RG-6324) is a GPRC5DxCD3 T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
    Forimtamig
  • HY-P990095
    Vonsetamig
    		Inhibitor
    Vonsetamig is a humanised immunoglobulin G4-kappa, anti-TNFRSF17 and CD3E bispecific antibody. Vonsetamig is an antineoplastic.
    Vonsetamig
  • HY-P990920
    Gocatamig
    		Inhibitor ≥99.0%
    HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody.
    Gocatamig
  • HY-P990717
    Brenetafusp
    		Inhibitor
    Brenetafusp is a type of TCR/anti-CD3 bispecific fusion protein. Brenetafusp targets intracellularly derived peptides presented at the tumor cell surface in complex with human leukocyte antigen (HLA).
    Brenetafusp
  • HY-P990932
    Obrixtamig
    		Inhibitor
    HY-P990932 is an CD3E/DLL3-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibodychimeric antibody.
    Obrixtamig
  • HY-P99562
    Tidutamab
    Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC).
    Tidutamab
  • HY-P99776
    Plamotamab
    		Inhibitor 99.12%
    Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo.
    Plamotamab
  • HY-P990272
    Anti-Mouse CD3ε Antibody (KT3)
    		Inhibitor
    Anti-Mouse CD3ε Antibody (KT3) is a rat-derived IgG2a type antibody inhibitor, targeting to mouse CD3ε. Anti-Mouse CD3ε Antibody (KT3) increases thymocytes proliferation. Anti-Mouse CD3ε Antibody (KT3) can be used for the research of immunology.
    Anti-Mouse CD3ε Antibody (KT3)
  • HY-P99837
    Dafsolimab
    Dafsolimab (SPV-T3a) is a Mouse IgG2b monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/T cell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD).
    Dafsolimab
  • HY-P991197
    Anti-GPRC5D Antibody
    		Inhibitor
    Anti-GPRC5D Antibody is a humanized IgG1 monoclonal antibody that targets GPRC5D. Anti-GPRC5D Antibody is the antibody part of the ADC molecule LM-305. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-GPRC5D Antibody
  • HY-P991122
    Besufetamig
    		Ligand 99.98%
    Besufetamig is a bispecific antibody targeting programmed cell death 1 (PD-1) and CD3ε chain. Besufetamig modulates the activity of immune cells, exerting immunosuppressive and antineoplastic activities. Besufetamig is promising for research of cancers.
    Besufetamig
  • HY-P991183
    SAR-442257
    		Inhibitor ≥99.0%
    SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on T cells.
    SAR-442257
  • HY-P990925
    Linclatamig
    		Inhibitor
    HY-P990925 is an CD3E-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
    Linclatamig
  • HY-P990981
    Clesitamig
    Clesitamig is a DLL3/CD3/CD137 trispecific T cell engager, consisting of two CD3/CD137 dual-specific antigen-binding fragments (Fabs) and one additional DLL3 antigen-binding fragment (Fab). Clesitamig exhibits potent antitumor activity and can be used in research on tumors such as small cell lung cancer.
    Clesitamig
  • HY-P991089
    GEN-1044
    		Inhibitor 98.83%
    GEN-1044 is a bispecific CD3 and oncofetal antigen 5T4 antibody. GEN-1044 shows immunomodulating and antineoplastic activities.
    GEN-1044
  • HY-P991088
    HPN536
    		Inhibitor 99.00%
    HPN536 is a trispecific, T-cell-activating protein-based construct, which binds to mesothelin-expressing tumor cells, CD3ε on T cells, and to serum albumin. HPN536 specifically redirects T cells for potent redirected lysis of mesothelin-expressing cancer cells with concomitant T-cell activation.
    HPN536
  • HY-P990903
    Avitotamig
    		Inhibitor
    HY-P990903 is an CD3E/CD33-targeting [H-γ1 _ L-κ-scFv heavy -κ]-dimer type bispecific antibody.
    Avitotamig
  • HY-P991209
    Nebratamig
    		Inhibitor
    Nebratamig (GNC-035) is an anti-ROR1/anti-CD3/anti-PD-L1/anti-4-1BB tetra-specific antibody with potential immunostimulatory and antineoplastic activities.
    Nebratamig
Cat. No. Product Name / Synonyms Application Reactivity